Medicinova Inc (MNOV)

$2.42 +0.40 (19.80%)
Market Cap 92.04M
Revenue (ttm) 410,000.00
Net Income (ttm) -12.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,926.83%
Debt to Equity Ratio 0.00
Volume 1,117,309
Avg Vol 48,256
Day's Range N/A - N/A
Shares Out 49.22M
Stochastic %K 92%
Beta 0.63
Analysts Strong Sell
Price Target $9.00

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, an...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 373 1500
Fax: 858 404 0048
Address:
4275 Executive Square, Suite 300, La Jolla, United States
jones_
jones_ Sep. 16 at 6:56 PM
$MNOV good volume today
0 · Reply
Stackingg
Stackingg Sep. 16 at 6:52 PM
$MNOV
0 · Reply
Lionish
Lionish Sep. 16 at 3:09 PM
$MNOV A sleeping giant finally making a move after years of waiting.
1 · Reply
FlippinLinknz
FlippinLinknz Sep. 16 at 3:03 PM
$CIFG $MNOV . Gains locked in on both. Lets see if the stop losses holds by eod. Wheee
0 · Reply
DylanGFM
DylanGFM Sep. 16 at 2:48 PM
Check out medicine Nova $MNOV strong follow through on the daily $NRXS $MEDS
0 · Reply
jones_
jones_ Sep. 16 at 2:46 PM
$MNOV
1 · Reply
LXP
LXP Sep. 16 at 2:45 PM
$MNOV well damn. Too bad i only brought a starter pack. Data must have leaked
1 · Reply
jones_
jones_ Sep. 16 at 1:46 PM
$MNOV
0 · Reply
jones_
jones_ Sep. 16 at 8:43 AM
$MNOV 💪💪💪
0 · Reply
Moolababie815
Moolababie815 Sep. 16 at 3:38 AM
$MNOV couldn’t pull the trigger at 1.50, now I’m getting fomo 🤧. give me a little pullback so I can enter 🙏
0 · Reply
Latest News on MNOV
MediciNova Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 11, 2026, 7:00 AM EDT - 5 days ago

MediciNova Transcript: H.C. Wainwright 28th Annual Global Investment Conference

MediciNova to Participate in Two Investor Conferences in September

Sep 8, 2026, 6:00 AM EDT - 8 days ago

MediciNova to Participate in Two Investor Conferences in September

MNOV

MediciNova Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

MediciNova Quarterly report: Q2 2026

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

Jul 15, 2026, 8:00 AM EDT - 2 months ago

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOV

MediciNova CEO Provides Shareholder Update

Jun 30, 2026, 8:00 AM EDT - 2 months ago

MediciNova CEO Provides Shareholder Update

MNOV

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Jun 8, 2026, 8:00 AM EDT - 3 months ago

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MNOV

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

May 26, 2026, 7:00 PM EDT - 3 months ago

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOV

MediciNova Slides: Corporate presentation

May 26, 2026, 7:00 AM EDT - 3 months ago

MediciNova Slides: Corporate presentation

MediciNova Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 months ago

MediciNova Quarterly report: Q1 2026

MediciNova Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

MediciNova Proxy statement: Proxy filing

MediciNova Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

MediciNova Proxy statement: Proxy filing

MediciNova’s peer-reviewed ibudilast study advances clinical translation

2026-04-27T23:15:15.000Z - 4 months ago

MediciNova’s peer-reviewed ibudilast study advances clinical translation

MNOV

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

Apr 27, 2026, 7:00 PM EDT - 4 months ago

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MNOV

MediciNova Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

MediciNova Proxy statement: Proxy filing

MediciNova Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

MediciNova Proxy statement: Proxy filing

Maxim resumes MediciNova at Buy on potential value-driving data events this year

2026-03-23T12:45:43.000Z - 5 months ago

Maxim resumes MediciNova at Buy on potential value-driving data events this year

MNOV

MediciNova resumed with a Buy at Maxim

2026-03-23T11:36:21.000Z - 5 months ago

MediciNova resumed with a Buy at Maxim

MNOV

MediciNova to Participate at the 38th Annual ROTH Conference

Mar 16, 2026, 7:00 AM EDT - 6 months ago

MediciNova to Participate at the 38th Annual ROTH Conference

MNOV

MediciNova initiated with a Buy at H.C. Wainwright

2026-03-16T10:15:52.000Z - 6 months ago

MediciNova initiated with a Buy at H.C. Wainwright

MNOV

MediciNova management to meet with Maxim

2026-02-26T14:25:55.000Z - 6 months ago

MediciNova management to meet with Maxim

MNOV

MediciNova Annual report: Q4 2025

Feb 20, 2026, 7:00 AM EST - 6 months ago

MediciNova Annual report: Q4 2025

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

Jan 29, 2026, 6:00 PM EST - 7 months ago

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

MNOV

MediciNova issues letter to shareholders

2026-01-06T14:15:37.000Z - 8 months ago

MediciNova issues letter to shareholders

MNOV

2026 New Year's Greetings from the CEO

Jan 6, 2026, 9:00 AM EST - 8 months ago

2026 New Year's Greetings from the CEO

MNOV

MediciNova initiated with a Buy at Lucid Capital

2026-01-05T11:41:10.000Z - 8 months ago

MediciNova initiated with a Buy at Lucid Capital

MNOV

MediciNova completes patient enrollment in neuropathy trial of MN-166

2025-12-18T11:10:11.000Z - 9 months ago

MediciNova completes patient enrollment in neuropathy trial of MN-166

MNOV

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Dec 18, 2025, 6:00 AM EST - 9 months ago

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MNOV

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

Dec 8, 2025, 6:00 AM EST - 9 months ago

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MNOV

MediciNova files $300M mixed securities shelf

2025-12-05T21:30:10.000Z - 9 months ago

MediciNova files $300M mixed securities shelf

MNOV

MediciNova Registration statement: Registration filing

Dec 5, 2025, 7:00 AM EST - 9 months ago

MediciNova Registration statement: Registration filing

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

2025-11-18T11:10:40.000Z - 10 months ago

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

MNOV

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Nov 18, 2025, 6:00 AM EST - 10 months ago

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

MNOV

MediciNova Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

MediciNova Quarterly report: Q3 2025

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

Nov 6, 2025, 6:00 PM EST - 10 months ago

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

MNOV

MediciNova completes patient enrollment in MN-001-NATG-202 trial

2025-11-04T12:41:08.000Z - 10 months ago

MediciNova completes patient enrollment in MN-001-NATG-202 trial

MNOV

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

2025-10-31T00:55:15.000Z - 10 months ago

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

MNOV

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Oct 30, 2025, 7:00 PM EDT - 10 months ago

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

MNOV

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Oct 6, 2025, 8:00 AM EDT - 11 months ago

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

MNOV

MediciNova completes patient enrollment in COMBAT-ALS Phase 2b/3 trial

2025-09-22T12:15:46.000Z - 11 months ago

MediciNova completes patient enrollment in COMBAT-ALS Phase 2b/3 trial

MNOV

MediciNova provides update on SEPA, COMBAT-ALS trial enrollment

2025-09-08T13:05:11.000Z - 1 year ago

MediciNova provides update on SEPA, COMBAT-ALS trial enrollment

MNOV

MediciNova Provides Shareholder Update on Key Developments

Sep 8, 2025, 9:00 AM EDT - 1 year ago

MediciNova Provides Shareholder Update on Key Developments

MNOV

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 1 year ago

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MNOV

MediciNova achieves enrollment in COMBAT-ALS clinical trial

2025-08-27T03:50:11.000Z - 1 year ago

MediciNova achieves enrollment in COMBAT-ALS clinical trial

MNOV

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

Aug 26, 2025, 7:00 PM EDT - 1 year ago

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

MNOV

MediciNova files to sell 25M shares of common stock for holders

2025-08-22T20:25:09.000Z - 1 year ago

MediciNova files to sell 25M shares of common stock for holders

MNOV

MediciNova Registration statement: Registration filing

Aug 22, 2025, 8:00 AM EDT - 1 year ago

MediciNova Registration statement: Registration filing

MediciNova Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

MediciNova Quarterly report: Q2 2025

MediciNova enters $30M equity purchase agreement

2025-07-31T23:50:31.000Z - 1 year ago

MediciNova enters $30M equity purchase agreement

MNOV

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

Jul 31, 2025, 7:30 PM EDT - 1 year ago

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MNOV

MediciNova provides enrollment update for two key ongoing clinical trials

2025-07-24T10:16:32.000Z - 1 year ago

MediciNova provides enrollment update for two key ongoing clinical trials

MNOV

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Jul 24, 2025, 6:00 AM EDT - 1 year ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MNOV

MediciNova Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

MediciNova Quarterly report: Q1 2025

MediciNova Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

MediciNova Proxy statement: Proxy filing

MediciNova Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

MediciNova Proxy statement: Proxy filing

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Apr 14, 2025, 7:00 PM EDT - 1 year ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

MNOV

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Apr 8, 2025, 7:00 PM EDT - 1 year ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MNOV

MediciNova Annual report: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

MediciNova Annual report: Q4 2024

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Dec 5, 2024, 6:00 PM EST - 1 year ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MNOV

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Nov 14, 2024, 6:00 PM EST - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MNOV

MediciNova Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

MediciNova Quarterly report: Q3 2024

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Nov 11, 2024, 6:00 PM EST - 1 year ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MNOV

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Oct 23, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MNOV

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Sep 30, 2024, 9:00 AM EDT - 1 year ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MNOV

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Sep 9, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MNOV

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Sep 3, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MNOV

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Aug 29, 2024, 7:00 PM EDT - 2 years ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MNOV

MediciNova Quarterly report: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

MediciNova Quarterly report: Q2 2024

MediciNova Chief Business Officer David H. Crean, Ph.D.

Jun 20, 2024, 6:00 AM EDT - 2 years ago

MediciNova Chief Business Officer David H. Crean, Ph.D.

MNOV

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MNOV

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Jun 3, 2024, 6:00 AM EDT - 2 years ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MNOV

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

May 28, 2024, 6:00 AM EDT - 2 years ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

MNOV

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

May 20, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MNOV

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

May 14, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MNOV

MediciNova Quarterly report: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

MediciNova Quarterly report: Q1 2024

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

May 7, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MNOV

MediciNova Proxy statement: Proxy filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

MediciNova Proxy statement: Proxy filing

MediciNova Proxy statement: Proxy filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

MediciNova Proxy statement: Proxy filing

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Apr 2, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MNOV

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Mar 26, 2024, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MNOV

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Mar 20, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MNOV

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Mar 12, 2024, 6:30 AM EDT - 2 years ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MNOV

MediciNova Annual report: Q4 2023

Feb 15, 2024, 7:00 AM EST - 2 years ago

MediciNova Annual report: Q4 2023

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Jan 17, 2024, 6:00 AM EST - 2 years ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MNOV

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Dec 21, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MNOV

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Dec 6, 2023, 6:00 PM EST - 2 years ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MNOV

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Nov 19, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

MNOV

MediciNova Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

MediciNova Quarterly report: Q3 2023

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Oct 27, 2023, 1:00 AM EDT - 2 years ago

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

MNOV

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Oct 10, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MNOV

MediciNova Receives Gene Therapy Milestone Payment

Oct 4, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives Gene Therapy Milestone Payment

MNOV

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Sep 27, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MNOV

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Aug 17, 2023, 7:00 PM EDT - 3 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MNOV

jones_
jones_ Sep. 16 at 6:56 PM
$MNOV good volume today
0 · Reply
Stackingg
Stackingg Sep. 16 at 6:52 PM
$MNOV
0 · Reply
Lionish
Lionish Sep. 16 at 3:09 PM
$MNOV A sleeping giant finally making a move after years of waiting.
1 · Reply
FlippinLinknz
FlippinLinknz Sep. 16 at 3:03 PM
$CIFG $MNOV . Gains locked in on both. Lets see if the stop losses holds by eod. Wheee
0 · Reply
DylanGFM
DylanGFM Sep. 16 at 2:48 PM
Check out medicine Nova $MNOV strong follow through on the daily $NRXS $MEDS
0 · Reply
jones_
jones_ Sep. 16 at 2:46 PM
$MNOV
1 · Reply
LXP
LXP Sep. 16 at 2:45 PM
$MNOV well damn. Too bad i only brought a starter pack. Data must have leaked
1 · Reply
jones_
jones_ Sep. 16 at 1:46 PM
$MNOV
0 · Reply
jones_
jones_ Sep. 16 at 8:43 AM
$MNOV 💪💪💪
0 · Reply
Moolababie815
Moolababie815 Sep. 16 at 3:38 AM
$MNOV couldn’t pull the trigger at 1.50, now I’m getting fomo 🤧. give me a little pullback so I can enter 🙏
0 · Reply
thepalace2007
thepalace2007 Sep. 16 at 1:59 AM
$MNOV homerun stock here
0 · Reply
jones_
jones_ Sep. 15 at 2:11 PM
$MNOV above the weekly 200EMA @ $1.96
0 · Reply
MingChoo
MingChoo Sep. 13 at 1:51 PM
$MNOV On close watch7
0 · Reply
jones_
jones_ Sep. 9 at 12:28 PM
$MNOV
1 · Reply
jones_
jones_ Sep. 8 at 4:49 PM
$MNOV breaking out
1 · Reply
jltransport
jltransport Sep. 4 at 4:48 PM
$MNOV im interested in this stock. Jump in or not?
3 · Reply
jones_
jones_ Sep. 3 at 2:20 PM
$MNOV took a starter position
1 · Reply
mfglola
mfglola Sep. 2 at 4:49 PM
$MNOV Hmm... now termination of the Yorkville standby equity purchase agreement. Good data and buyout or strategic partnership incoming?
0 · Reply
thepalace2007
thepalace2007 Aug. 25 at 12:46 PM
$MNOV 2 Green Day’s in a row…time to accumulate
1 · Reply
LXP
LXP Aug. 24 at 4:37 PM
$MNOV hhmmm. Unusual move. Higher volumes than I've seen
0 · Reply
mfglola
mfglola Aug. 20 at 8:58 PM
$MNOV New executive employment agreements with increased severance. Perhaps great NAFLD results around the corner and a buyout?
1 · Reply
Amoore0107
Amoore0107 Aug. 13 at 3:08 PM
$MNOV 💸 💰
0 · Reply